These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33466831)

  • 1. Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson's Disease.
    Stanojlovic M; Pallais JP; Kotz CM
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Sociability and Social Memory Impairment in the A53T Mouse Model of Parkinson's Disease Are Ameliorated by Chemogenetic Modulation of Orexin Neuron Activity.
    Stanojlovic M; Pallais Yllescas JP; Vijayakumar A; Kotz C
    Mol Neurobiol; 2019 Dec; 56(12):8435-8450. PubMed ID: 31250383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson's disease.
    Stanojlovic M; Pallais JP; Lee MK; Kotz CM
    Mol Brain; 2019 Oct; 12(1):87. PubMed ID: 31666100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemogenetic Modulation of Orexin Neurons Reverses Changes in Anxiety and Locomotor Activity in the A53T Mouse Model of Parkinson's Disease.
    Stanojlovic M; Pallais JP; Kotz CM
    Front Neurosci; 2019; 13():702. PubMed ID: 31417337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemogenetic activation of orexin/hypocretin neurons ameliorates aging-induced changes in behavior and energy expenditure.
    Stanojlovic M; Pallais Yllescas JP; Mavanji V; Kotz C
    Am J Physiol Regul Integr Comp Physiol; 2019 May; 316(5):R571-R583. PubMed ID: 30726119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.
    Henrich MT; Geibl FF; Lee B; Chiu WH; Koprich JB; Brotchie JM; Timmermann L; Decher N; Matschke LA; Oertel WH
    Acta Neuropathol Commun; 2018 May; 6(1):39. PubMed ID: 29747690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.
    Butkovich LM; Houser MC; Chalermpalanupap T; Porter-Stransky KA; Iannitelli AF; Boles JS; Lloyd GM; Coomes AS; Eidson LN; De Sousa Rodrigues ME; Oliver DL; Kelly SD; Chang J; Bengoa-Vergniory N; Wade-Martins R; Giasson BI; Joers V; Weinshenker D; Tansey MG
    J Neurosci; 2020 Sep; 40(39):7559-7576. PubMed ID: 32868457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson's disease mouse model.
    Wang W; Song N; Jia F; Tang T; Bao W; Zuo C; Xie J; Jiang H
    Neurochem Int; 2018 Mar; 114():71-79. PubMed ID: 29355568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retina as a Model to Study In Vivo Transmission of α-Synuclein in the A53T Mouse Model of Parkinson's Disease.
    Mammadova N; Baron T; Verchère J; Greenlee JJ; Greenlee MHW
    Methods Mol Biol; 2021; 2224():75-85. PubMed ID: 33606207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.
    Paumier KL; Sukoff Rizzo SJ; Berger Z; Chen Y; Gonzales C; Kaftan E; Li L; Lotarski S; Monaghan M; Shen W; Stolyar P; Vasilyev D; Zaleska M; D Hirst W; Dunlop J
    PLoS One; 2013; 8(8):e70274. PubMed ID: 23936403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic abnormalities and hypoleptinemia in α-synuclein A53T mutant mice.
    Rothman SM; Griffioen KJ; Fishbein KW; Spencer RG; Makrogiannis S; Cong WN; Martin B; Mattson MP
    Neurobiol Aging; 2014 May; 35(5):1153-61. PubMed ID: 24239384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function.
    Oaks AW; Frankfurt M; Finkelstein DI; Sidhu A
    PLoS One; 2013; 8(4):e60378. PubMed ID: 23560093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonergic dysfunction in the A53T alpha-synuclein mouse model of Parkinson's disease.
    Deusser J; Schmidt S; Ettle B; Plötz S; Huber S; Müller CP; Masliah E; Winkler J; Kohl Z
    J Neurochem; 2015 Nov; 135(3):589-97. PubMed ID: 26201615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model.
    Gan L; Vargas MR; Johnson DA; Johnson JA
    J Neurosci; 2012 Dec; 32(49):17775-87. PubMed ID: 23223297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson's disease models.
    Jin JW; Fan X; Del Cid-Pellitero E; Liu XX; Zhou L; Dai C; Gibbs E; He W; Li H; Wu X; Hill A; Leavitt BR; Cashman N; Liu L; Lu J; Durcan TM; Dong Z; Fon EA; Wang YT
    Commun Biol; 2021 Feb; 4(1):232. PubMed ID: 33608634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice.
    Gu XL; Long CX; Sun L; Xie C; Lin X; Cai H
    Mol Brain; 2010 Apr; 3():12. PubMed ID: 20409326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic mild stress accelerates the progression of Parkinson's disease in A53T α-synuclein transgenic mice.
    Wu Q; Yang X; Zhang Y; Zhang L; Feng L
    Exp Neurol; 2016 Nov; 285(Pt A):61-71. PubMed ID: 27637804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.